In summary, our findings suggest that enhancing FoxO3 can effectively alleviate doxorubicin‐induced cardiomyopathy by activating autophagy and indicate that FoxO3 may represent a promising therapeutic target for the treatment of heart disease, particularly DOX‐induced cardiomyopathy in clinical practice. Here, FOXO3 is linked to cardiomyopathy.